- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.12.25 | Roquefort Theraptcs. - Clinical Trial & License Agreement Update | - | RNS | ||
| 11.12.25 | XFRA NEW INSTRUMENTS AVAILABLE ON 11.12.2025 | 399 | Xetra Newsboard | The following instruments on XETRA do have their first trading 11.12.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 11.12.2025
Aktien
1 AU0000410128 Ariana Resources PLC
2... ► Artikel lesen | |
| 09.12.25 | Roquefort Theraptcs. - Conversion of CLNs | - | RNS | ||
| 01.12.25 | Roquefort Therapeutics: Aktie handelt ab heute ex-Anspruch auf unkotierte Aktien | 1 | Investing.com Deutsch | ||
| 01.12.25 | Roquefort Therapeutics shares marked ex-entitlement for unlisted shares | 1 | Investing.com | ||
| 01.12.25 | Roquefort Theraptcs. - Ex-Entitlement Date - Unlisted RNV Shares | - | RNS | ||
| ROQUEFORT THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 01.12.25 | Roquefort Theraptcs. - Determination of Record Date and Entitlement | - | RNS | ||
| 24.11.25 | Director dealings: Roquefort Therapeutics director raises stake | 1 | Sharecast | ||
| 24.11.25 | Roquefort Theraptcs. - Director/PDMR Shareholding | - | RNS | ||
| 18.11.25 | Roquefort Theraptcs. - Executed License Agreement & Transaction Update | - | RNS | ||
| 03.11.25 | Roquefort Theraptcs. - MK Cell Out-License & Lyramid SPA Update | - | RNS | ||
| 16.10.25 | Roquefort Therapeutics beschafft 300.000 £ für Akquisition von Krebsmedikament | 1 | Investing.com Deutsch | ||
| 16.10.25 | Roquefort Therapeutics raises £300,000 to fund cancer drug acquisition | 2 | Investing.com | ||
| 16.10.25 | Roquefort Theraptcs. - Fundraise & Transaction Update | - | RNS | ||
| 30.09.25 | EARNINGS: Billington profit dives; Emmerson and Roquefort Therapeutics narrow loss | 2 | Alliance News | ||
| 30.09.25 | Roquefort Theraptcs. - Interim Results to 30 June 2025 | - | RNS | ||
| 24.09.25 | Roquefort Theraptcs. - Investor Presentation via Engage Investor | - | RNS | ||
| 08.09.25 | Roquefort Therapeutics shares surge on Coiled USA reverse takeover proposal | 1 | Alliance News | ||
| 08.09.25 | Roquefort Theraptcs. - Proposed Acquisition of Clinical Stage Company | - | RNS | ||
| 28.08.25 | Roquefort Therapeutics further extends deadline for Lyramid sale deal | 1 | Alliance News |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MONTE ROSA THERAPEUTICS | 23,280 | 0,00 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects | In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1/IL-6 driven inflammatory diseases, demonstrated... ► Artikel lesen | |
| NUVALENT | 106,82 | +9,90 % | Royalty Pharma plc: Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million | NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib from an... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 13,730 | 0,00 % | Ventyx Biosciences und BioAge Labs: Tenbagger-Rendite im No Brainer Club! | Mit Ventyx Biosciences feiert der No Brainer Club eine waschechte Tenbagger-Empfehlung: Nach Übernahmegerüchten springt die Aktie heute im regulären Handel zunächst um rund 30% nach oben, bevor sie... ► Artikel lesen | |
| COGENT BIOSCIENCES | 36,270 | +4,28 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis | WALTHAM, Mass. and BOULDER, Colo., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
| ERASCA | 5,170 | 0,00 % | Erasca stock pulls back after 25% jump, Stifel cites competitor data | ||
| ALUMIS | 17,920 | 0,00 % | Should You Chase the Rally in Alumis Stock Today? | ||
| AVIDITY BIOSCIENCES | 72,37 | +0,17 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 76,69 | +4,40 % | Wolfe Research stuft Kymera Therapeutics wegen fehlender Impulse herab | ||
| RECURSION PHARMACEUTICALS | 4,860 | 0,00 % | JPMorgan Boosts Rating on Recursion Pharmaceuticals (RXRX) Amid AI-Driven Drug Pipeline | ||
| TANGO THERAPEUTICS | 11,790 | 0,00 % | Tango Therapeutics Sub, Inc: Tango Therapeutics Appoints Sung Lee to Board of Directors | ||
| QIAGEN | 40,245 | +0,65 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 07.01.2026 | Das Instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON EQUITY wird cum Kapitalmassnahme gehandelt am 07.01.2026 und ex Kapitalmassnahme am 08.01.2026 The instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 292,53 | 0,00 % | Praxis Precision Prices $575 Mln Public Offering At $260/shr | ||
| ADMA BIOLOGICS | 18,820 | +2,62 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| VERA THERAPEUTICS | 48,680 | +4,64 % | Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy | FDA assigned PDUFA target action date of July 7, 2026.If approved, atacicept would be the first B cell modulator targeting both BAFF and APRIL for IgAN.Atacicept received FDA Breakthrough Therapy... ► Artikel lesen | |
| DYNE THERAPEUTICS | 19,390 | +7,01 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares | WALTHAM, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven... ► Artikel lesen |
Das Unternehmen ROQUEFORT THERAPEUTICS PLC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,011 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ROQUEFORT THERAPEUTICS PLC finden Sie auf Wallstreet Online.